Characteristics of Cutaneous Marginal Zone Lymphomas With Marked Plasmacytic Differentiation and a T Cell-Rich Background

Departmentsof Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
American Journal of Clinical Pathology (Impact Factor: 2.51). 01/2010; 133(1):59-69. DOI: 10.1309/AJCPW64FFBTTPKFN
Source: PubMed


Primary cutaneous marginal zone lymphoma (MZL) is a common B-cell lymphoma of skin and is characterized by an infiltrate of neoplastic marginal zone B cells typically within the marginal zones of reactive lymphoid follicles and the interfollicular region. However, in our experience, many cases have underemphasized features such as marked plasmacytic differentiation and/or a prominent T-cell component, which may obscure the neoplastic B cells and lead to misdiagnosis. We wanted to draw attention to these features and have studied 15 cases of MZL with marked plasmacytic differentiation, 10 of which had numerous T cells, some with cytologic atypia, and few B cells in the interfollicular region. Plasma cells were monotypic in all cases by in situ hybridization. By polymerase chain reaction, 6 of 8 T cell-rich cases had an IGH gene rearrangement, and none were clonal for T-cell receptor gene. We discuss the terminology, morphologic features, molecular profile, behavior, and differential diagnosis of cutaneous MZL.

Full-text preview

Available from:
  • Source

  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary cutaneous B-cell lymphomas (PCBCL) represent a heterogeneous group of lymphoproliferative disorders characterized by clonal proliferation of neoplastic B-cells in the skin. The recent joint World Health Organization (WHO) and European Organization for the Research and Treatment of Cancer (EORTC) classification recognizes three major subgroups of PCBCL: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone B-cell lymphoma (PCMZL) and primary cutaneous large B-cell lymphoma, leg type (PCLBCL-LT). Recent advances in the field and the availability of new methodological tools have greatly enhanced our insights into the biology of cutaneous B-cell lymphomas and allow a more precise definition of these entities. Considerable progress over the past decade has led to significantly improved diagnostic accuracy allowing earlier diagnosis, targeted strategies and improved therapeutic results in the management of primary cutaneous B-cell lymphomas. This review presents an overview of primary cutaneous B-cell lymphomas with an emphasis on the proper incorporation of current and emerging diagnostic tools into the work-up and classification of this group of unique malignancies.
    Giornale Italiano di Dermatologia e Venereologia 06/2010; 145(3):361-73. · 0.68 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: IntroductionIn this era of precision medicine, targets for new drugs are to be found across the range of tumors. Tissue microarrays are often used for that purpose, and for instance, Fernandez et al. [1] stained 395 lymphomas for Bruton’s tyrosine kinase protein expression showing that many B cell lymphomas, some T cell lymphomas, 14/16 nodular lymphocyte predominant, and 6/27 classic Hodgkin lymphoma (cHL) were positive. However, expression of a protein does not fully correlate with therapy response, so such studies can only serve as an initial screen. A next step is to study the effect of a drug in cell lines, like the work of Choudhary et al. [2], who investigated the effect of a Bcl-2 inhibitor on B cell lymphoma cell lines and also the acquired resistance after treatment. They showed that the B cell lymphoma cells upon treatment with Bcl-2 inhibition increased their expression of MCL-1 and Bcl-x, which resulted in resistance that could be overcome by inhibition of these factors. T ...
    Journal of Hematopathology 06/2010; 3(1):47-58. DOI:10.1007/s12308-010-0060-x
Show more